Entities

Earthling VC is a pre-seed venture capital firm investing in emerging computing technologies that connect digital systems with the physical world. Its focus includes AI, robotics, augmented and virtual reality, and biotechnology. It was founded by Arian Ghashghai, previously a machine-learning engineer at Meta Reality Labs.

Blue Lake VC invests in immigrant founders building B2B software companies in the United Kingdom. It focuses on pre-seed and seed investments and provides founder support and access to its international network. Its portfolio includes AI video-intelligence company Imaginario AI.

Microsoft AI vice president and a publicly named individual investor in Deplike.

Udemy co-founder and a publicly named individual investor in Deplike.

Gram Games co-founder and a publicly named individual investor in Deplike.

Yemeksepeti co-founder and a publicly named individual investor in Deplike.

Deplike develops music-learning and guitar software. Its Chordie AI product combines personalized AI learning paths, real-time feedback, 3D tutors and game mechanics to help people learn guitar through songs. The company also offers guitar effects and audio tools for mobile devices and digital audio workstations.

Addvocate builds AI sales systems that analyze CRM records, calls, emails and buyer activity to help revenue teams prepare meetings, follow up and manage deals. Its Nudge product uses agents to turn sales signals into work in existing business tools. The company is SAS Addvocate, registered in Paris in 2024, with product development in Tunis.

Imaginario AI develops video-intelligence software that indexes speech, visuals, sounds and people so media teams can find and reuse footage. Its platform connects video storage and media-management systems to editing tools, with search, clipping and agent-assisted story assembly. Founded in 2022, it is a Delaware company with its team in London.

RoboCare is a Sfax-based precision-agriculture company founded in 2020. It combines spectral imaging, satellite and drone data, connected sensors and AI to help farmers monitor plant health, detect crop stress and manage irrigation, pesticides and fertilizers. Its platform serves farms and agribusinesses in North Africa and the Middle East.

Develops AI-assisted blood biomarker diagnostics for early detection and risk assessment of neurodegenerative diseases, including Alzheimer’s. Its research combines nanoscale sensing, blood-based biomarkers and machine learning to make screening more accessible; the diagnostic platform is undergoing development and clinical validation.

eSteps Health develops smart insoles, a mobile app and a clinician dashboard for monitoring gait and mobility between visits. Its platform combines movement sensors and AI analysis to support rehabilitation and mobility assessment, including applications for neurological movement disorders. Founded from University of Bologna biomechanics research in 2020, it moved its base to Boston in 2022 while retaining research and engineering in Italy.

216 Capital is a Tunis-based venture capital firm investing in early-stage technology companies from Tunisia and other markets. Its sector-spanning portfolio includes AI tools, precision agriculture, energy technology and digital health, with support for fundraising, commercial partnerships and international expansion.

Nada Bendhaw is published by VU Venture Partners as Healthcare Team Member (published investment affiliation). The current manager page places this named professional within its Healthcare Team. This is a source-published investment-team affiliation, not proof of permanent employment, a statutory manager/director appointment or individual investment authority. The manager-linked professional profile and individually associated original portrait support the published identity, while a full career chronology and exact joining day are not supplied.

Safa Tlijani is published by VU Venture Partners as ClimateTech Team Member (published investment affiliation). The current manager page places this named professional within its ClimateTech Team. This is a source-published investment-team affiliation, not proof of permanent employment, a statutory manager/director appointment or individual investment authority. The manager-linked professional profile and individually associated original portrait support the published identity, while a full career chronology and exact joining day are not supplied.

Manages public equity portfolios and venture funds investing in Indian technology companies. Its private-market strategies back proprietary deep tech in AI, space, semiconductors, electronics, defence, fintech infrastructure and biosciences, combining early-stage investing with growth financing.

Develops small molecule modulators of the adenosine pathway for cancer immunotherapy, aiming to reverse adenosine-driven suppression of the immune response within tumours.

Develops and commercialises medicines that inhibit the complement immune system, including treatments for geographic atrophy and paroxysmal nocturnal haemoglobinuria. Biogen completed its acquisition of Apellis on 14 May 2026.

Develops small molecule medicines targeting free fatty acid receptors for metabolic and inflammatory diseases. Its research includes FFA4 agonists for non-alcoholic steatohepatitis and approaches to type 2 diabetes, based on work at the Universities of Glasgow and Southern Denmark.

Developed small molecule kinase inhibitors for inflammatory, immunological and cancer indications, including MK-2, JAK and ITK programs. Aclaris Therapeutics acquired the company in August 2017 and retained its drug discovery and contract research teams.

Develops targeted molecular agents for image-guided cancer detection and therapy. The University of Edinburgh spinout works on fluorescent optical imaging and radiotherapeutic agents based on c-Met targeting.

Developed an image-guided device for minimally invasive, beating-heart repair of degenerative mitral regurgitation. Its system stabilises a prolapsed mitral valve leaflet without stopping the heart. Edwards Lifesciences acquired Harpoon in December 2017.

Developed inhibitors of kynurenine 3-monooxygenase to treat inflammation, including the investigational KNS366 program for acute pancreatitis. Dr. Falk Pharma acquired and integrated the University of Edinburgh spinout in October 2024; its scientific founders remained consultants to the acquirer.

Developed synthetic bone graft substitutes based on advanced nanostructures to support bone regeneration. Its University of Aberdeen research led to the Osteo3 ZP Putty technology. OssDsign acquired SIRAKOSS in November 2020.

Gerald Chan co-founded Morningside with Ronnie Chan in 1986. He is publicly identified as Morningside chairman by its own digital-health summit team and as co-founder by Neutrolis and the American Academy of Arts and Sciences. He holds a doctorate in radiation biology from Harvard; his investing spans biotechnology, neuroscience and technology. Existing Apellis board affiliation is preserved.

Stephanie Monaghan O’Brien has been a member of the Morningside investment team since 1997. Her work includes operational guidance and financing for science and technology companies. Vigeo identifies her Harvard undergraduate and NYU law degrees; the Catholic Community Fund explicitly identifies her current investment-professional affiliation with Morningside Technology Advisory LLC. Existing Apellis role is preserved.

Ilios Therapeutics develops multifunctional small molecules for neurodegenerative diseases. Its chemistry platform combines bioactive components to address protein mislocalization, oxidative stress and neuroinflammation, with a lead research program in ALS and frontotemporal dementia. It operates at Harvard's Pagliuca Life Lab in Boston.

Dementia Discovery Fund venture partner and neuroscientist with prior research leadership experience at Rodin Therapeutics, Satori Pharmaceuticals and Pfizer.

Luca Giani is a senior principal at Alumni Ventures, working with Green D Ventures and The Yard Ventures. His earlier biotechnology entrepreneurship includes founding and leading Ilios Therapeutics, which develops preclinical approaches to neurodegenerative disease. He has also worked in technology commercialisation, healthcare investing, M&A at Credit Suisse and strategy consulting at Bain. He is a Termeer Fellow and previously held Harvard fellowships in life-science entrepreneurship and technology policy.

Biotechnology executive and Schrödinger director, also listed as Rosana Kapeller. Co-founded ROME Therapeutics and previously served as founding chief scientific officer of Nimbus Therapeutics and research vice president at Aileron Therapeutics.

Develops oral small molecule therapies for neurodegenerative diseases using covalent chemistry to target disease-driving proteins. Its programs include ALS therapies aimed at reducing toxic TDP-43 buildup and treatments for Parkinson’s disease.

Develops cell-specific nucleic acid delivery technology for cancer and other cell and gene therapies. Its modular Zip-Code platform uses endogenous targeting mechanisms to deliver therapeutic payloads to selected cell types without viral vectors.

Develops an investigational catheter-based treatment for chronic obstructive pulmonary disease. Its therapeutic system aims to reduce symptoms and improve outcomes for patients whose disease cannot be adequately managed with medications and rehabilitation.

Develops regulatory T-cell therapies for autoimmune diseases. A University of Virginia spinout, it works on treatments that restore immune regulation rather than broadly suppressing the immune system.

Lucy Edwardes-Jones is a TRIMTECH non-executive director and BGF life-sciences investor. She supports several drug-discovery and biotechnology companies at board level. Before BGF, she worked in strategy consulting with a healthcare and pharmaceutical focus. BGF early-stage life-sciences investor based in London and the South East. Earlier experience includes five years at CIL. Current TRIMTECH board affiliation and authentic issuer portrait are retained separately.

Develops oral and intravenous anticoagulants that inhibit activated Factor XII to prevent dangerous blood clots while aiming to avoid the bleeding risk of existing treatments. The company is a University of Leeds spinout.

Develops small molecule medicines for hereditary kidney disease. Its LoAc drug candidates target abnormally high cAMP levels that drive fluid-filled cyst growth in autosomal dominant polycystic kidney disease.

Alan Naylor is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Following a long career culminating as Vice President and Director of Medicinal Chemistry at GSK, Alan is now an independent drug discovery consultant. He is a co-inventor of Serevent (salmeterol), a marketed drug for use in asthma and chronic obstructive pulmonary disease (COPD). As a consultant, Alan has provided scientific and strategic advice to a range of academic and industrial clients and has been a member of several scientific advisory boards including membership of Wellcome Trust and Cancer Research UK committees. He is also a co-founder and adviser to Pathios Therapeutics Ltd., an Oxford-based start-up focused on immunooncology. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check. Alan Naylor is advisor - united kingdom at Brandon Capital. His Brandon advisory affiliation dates to2015. His GSK medicinal-chemistry career includes drug-discovery leadership and co-invention of salmeterol; subsequent consulting and Pathios co-founding complement his existing Parkinson’s research and Lunac advisory roles. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Alex Mayweg is Versant Ventures’ current Managing Director. Joined2016 after Roche global chemistry leadership. Chemistry education spans Imperial College, Oxford doctorate and Stanford postdoctoral research.

NMD Pharma nonexecutive director with neuroscience and rare-disease drug-development and venture-investing experience. The current issuer biography identifies her 2026 return to Roche Venture Fund as Head of Venture Investments, following Rewind and Pureos work. Holds a neuroscience/biochemistry doctorate from Freie Universität Berlin and an IE Madrid MBA. Roche’s current primary directory names Anja Harmeier as Head of Roche Venture Fund. NMD Pharma’s own biography states she returned as head in2026. The prior NMD and Mironid biography, original conference portrait and all company roles are preserved; no exact return date or personal check is inferred.

Life-sciences investor and co-founder of Forbion, with experience in clinical development and biotechnology company governance.

Mervyn Turner, PhD, is a director of Amydis. He spent 27 years at Merck, including leadership of worldwide licensing and external research and service as its first Chief Strategy Officer, before retiring in 2011 and establishing MJ Turner Consulting. Mervyn Turner serves on Spinogenix’s board. He previously worked at Merck for 27 years, leading licensing and external research and serving as chief strategy officer before establishing an independent consultancy.

Draig Therapeutics founder and chief scientific officer, and Cardiff University Medicines Discovery Institute director. Specializes in AMPA receptor biology, medicinal chemistry and translational drug discovery.

Develops an intracellular drug discovery platform that screens cyclic peptides inside living mammalian cells to find functional modulators of difficult drug targets. Its Microcycles can serve as therapeutics or templates for small molecule drugs, with applications including cancer.

Develops small molecule medicines for respiratory diseases, including cystic fibrosis. Its ion-channel therapies aim to hydrate airway mucus and improve clearance; inhaled ENaC blocker ETD001 is in clinical development.

Develops investigational transcatheter devices for functional mitral regurgitation. Its CARLEN Cardiac Leaflet Enhancer augments a native mitral valve leaflet to restore valve function while preserving normal blood flow and options for later interventions.

Amrinder Singh is published by Vensana Capital as Partner. Investor with earlier Medtronic Ventures, strategy and remote-monitoring experience, preceded by Thoratec engineering and product work. UC Davis engineering graduate with a Kellogg MBA; existing NyraMedical directorship preserved.

Justin Klein is published by Vensana Capital as Co-founder and Managing Partner. Physician and lawyer with prior NEA medtech investing experience. Holds Duke undergraduate and medical degrees and a Harvard law degree. Existing NyraMedical board-observer identity is the same Vensana investor; the unrelated Health2047 engineering director is preserved separately. Justin Klein, MD, JD, serves on Cleerly’s board and co-founded Vensana Capital. He previously invested at NEA; he is distinct from Health2047’s engineer Justin Klein.

PfizerVentures primarypublished affiliation: Executive Director, WWBD / Partner. Marie-Claire Peakman, MRCPharm, PhD is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Curve Therapeutics, DEM Biopharma, Greywolf Therapeutics, Mediar Therapeutics, Mission Therapeutics, Mozart Therapeutics, Normunity, and TRIMTECH Therapeutics. Her prior investment responsibilities include Vaccine Company Inc. (acquired by LLY) and observer roles with Capstan Therapeutics (acquired by ABBV), TRex Bio and Crossbow Therapeutics. She is also responsible for managing our investment in the Andera Partners’ BioDiscovery 7 Fund and is a member of the advisory board for the CT Bioscience Innovation Fund. Marie-Claire brings over 25 years of experience at Pfizer, leading platform technology groups that support small molecule programs from idea to development candidate selection across all therapeutic areas. These teams, including the Primary Pharmacology Group which she founded in 2009, played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. Her experience extends to compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She has multiple roles on non-profit boards in the community. Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a Member of the Royal College of Pharmacy. Marie-Claire Peakman is a TRIMTECH non-executive director and Pfizer Ventures partner. Her Pfizer scientific leadership includes founding its Primary Pharmacology Group, followed by venture investment and portfolio oversight. She studied pharmacy and pharmacology at Nottingham and holds experience across discovery technologies and biotechnology boards.

Vento is an Exor-backed venture platform investing globally at pre-seed and seed stages in startups with at least one Italian founder. It invests across sectors, with AI and deep-tech companies among its holdings, and runs the Reef venture-building program and Wave technology event.

West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable medicines, serving pharmaceutical, biotechnology and medical-device companies. Its corporate development activities include early-stage investments in drug-delivery technology, including AcousticaBio.

Invests in early-stage European deep tech startups and venture funds commercialising scientific advances in advanced materials, waste valorisation and robotics. Its Capital business manages direct and hybrid funds, while its Catalyst connects startups with industrial customers and scientific partners to validate and scale technologies.

Develops bio-based aerogel insulation made from nanoporous biomaterials. Its lightweight, thin insulating materials target cold-chain packaging and transport, as well as buildings, to reduce energy use and material bulk.

Builds modular AI-enabled robots for ports and rail freight terminals. Its systems automate container twistlock handling, wagon pin flipping and gas inspection, while recording operational data and keeping terminal workers away from hazardous tasks.

Anja Leissner is published by byFounders as a member of its founder collective, described as founder based in Sweden. The collective provides experience and networks to portfolio companies; this is a network affiliation, not a manager employment title or a disclosed personal cash investment.

Develops wearable neuromuscular interfaces and a connected rehabilitation platform for stroke recovery. Its bracelet detects muscle activation and provides biofeedback to help patients reconnect movement intention with muscle activity, while clinicians monitor rehabilitation remotely.

Develops AI software for real-time monitoring and qualification of metal additive manufacturing. It analyses sensor data during printing to identify defects, create traceable quality records and reduce the time and cost of certifying complex components for aerospace, medical and energy applications.

Invests at pre-seed and seed in deep tech and AI startups applying frontier science and engineering to physical systems. The London firm draws on the Imperial College alumni community and connected founder networks.

Builds smart home energy controls, including the Tap intelligent light switch and TewkeAI contextual AI. Its hardware, sensors and software automate lighting and other home functions and help households shift electricity consumption to reduce costs and emissions.

Reinforced Ventures invests at the earliest stages in technical founders applying robotics and autonomous systems to physical-world problems. It supports portfolio companies with fundraising, technical networks and introductions to potential customers.

Founded in Quebec in 2020, Lime Health develops software for collecting and analyzing patient-reported experience and outcomes (PREMs and PROMs), including AI-assisted analysis. Its Emilia mobile application records medical consultations and generates summaries that patients can review and share with their care circle.

AcousticaBio is a Harvard spinout founded in 2022 developing acoustic fluid-processing technology for advanced biologic drug manufacturing. Its platform forms concentrated microparticle formulations intended to enable smaller-volume subcutaneous delivery of therapies otherwise administered intravenously.

Develops AI software that automates responses to corporate compliance questionnaires and other regulatory information requests, helping teams retrieve and reuse approved information.

Builds and invests in deep tech startups developing physical AI, energy technology, enterprise AI and logistics systems. Backed by Jungheinrich, it combines venture capital, company creation and partnerships with industrial customers.

Provides industrial DataOps software that integrates operational data, supports time-series and geospatial analytics and enables AI applications for industrial processes.

Provides software for autonomous enterprise drone operations, including remote fleet management, drone dock integration, inspection workflows and AI analysis of live video.

Provides AI-based learning and teacher support software. Its voice-first Tara platform offers spoken English practice, pronunciation feedback and institutional learning analytics.

Develops digital microscopes, whole-slide scanners and AI-assisted microscopy software for pathology, laboratory diagnostics and remote review of medical samples.

Develops wearable ECG devices, cloud software and AI analytics for continuous remote cardiac monitoring through its upBeat platform.

Provides collection, treatment and recycling systems for used menstrual hygiene products, recovering materials and supporting safer sanitary waste management.

Provides industrial maintenance software for asset management, lubrication programs, equipment inspections and safety compliance, with mobile workflows and AI assistance.

Develops flywheel energy storage systems using superconducting bearing technology for grid resilience, electric vehicle charging, data centers and industrial power applications.

Develops portable diagnostic tests and medical testing platforms that enable thyroid and other health measurements in clinics and at home.

Medical imaging software company combining AI and biomechanics to analyze aortic aneurysms from CT scans. Its cloud-based AiORTA suite supports anatomical assessment, surgical planning and research into tissue vulnerability and post-procedure monitoring.